索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]尹亮,刘德敏,谷国强.新型冠状病毒肺炎相关心肌损伤机制及治疗进展[J].国际心血管病杂志,2021,06:321-325.
点击复制

新型冠状病毒肺炎相关心肌损伤机制及治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2021年06期
页码:
321-325
栏目:
综述
出版日期:
2021-12-01

文章信息/Info

Title:
-
作者:
尹亮; 刘德敏; 谷国强
050000 石家庄,河北医科大学第二医院心内一科
Author(s):
-
关键词:
新型冠状病毒肺炎;  严重急性呼吸综合征冠状病毒2;  心肌损伤
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2021.06.001
文献标识码:
-
摘要:
新型冠状病毒肺炎(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,具有较高的传染性和致病性。COVID-19患者除有典型呼吸系统表现外,还可出现多种心肌损伤的表现。SARS-CoV-2可通过直接感染心肌、介导血管紧张素转化酶2(ACE2)下调、引起细胞因子风暴以及氧供需失衡等参与心肌损伤。深入了解COVID-19相关心肌损伤机制,有助于临床医生寻求更加精准的治疗方法以减轻心肌损伤。
Abstract:
-

参考文献/References

[1] Atzrodt CL, Maknojia I, Mccarthy R, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2[J]. FEBS J, 2020, 287(17):3633-3650.
[2] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273.
[3] Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and cardiovascular disease[J]. Circulation, 2020, 141(20):1648-1655.
[4] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(1229):1054-1062.
[5] Pavon AG, Meier D, Samin D, et al. First documentation of persistent SARS-Cov-2 infection persenting with late acute severe myocarditis[J]. Can J Cardio, 2020, 36(8): 1326.e5-1326.e7.
[6] Yang Y, Xiao Z, Ye K, et al. SARS-CoV-2: characteristics and current advances in research[J]. Virol J, 2020, 17(1):117.
[7] Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion[J]. Nature, 2020, 588(7837):327-330.
[8] Deng J, Wang DX, Deng W, et al. The effect of endogenous angiotensin Ⅱ on alveolar fluid clearance in rats with acute lung injury[J]. Can Respir J, 2012, 19(5):311-318.
[9] Nguyen Dinh CA, Montezano AC, Burger D, et al. Angiotensin Ⅱ, NADPH oxidase, and redox signaling in the vasculature[J]. Antioxid Redox Signal, 2013, 19(10):1110-1120.
[10] Arendse LB, Danser A, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure[J]. Pharmacol Rev, 2019, 71(4):539-570.
[11] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(1223):497-506.
[12] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China[J]. JAMA, 2020, 323(11):1061-1069.
[13] Sun SH, Chen Q, Gu HJ, et al. A mouse model of SARS-CoV-2 infection and pathogenesis[J]. Cell Host Microbe, 2020, 28(1):124-133.
[14] Escher F, Pietsch H, Aleshcheva G, et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies[J]. ESC Heart Fail, 2020, 7(5):2440-2447.
[15] Mckechnie JL, Blish CA. The innate immune system: fighting on the front lines or fanning the flames of COVID-19?[J]. Cell Host Microbe, 2020, 27(6):863-869.
[16] Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia[J]. J Infect Dis, 2020, 221(11):1762-1769.
[17] Chigusa S, Moroi T, Shoji Y. State-of-the-art calculation of the decay rate of electroweak vacuum in the standard model[J]. Phys Rev Lett, 2017, 119(21):211801.
[18] Sch?nrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps(NETs), and T cell suppression[J]. Adv Biol Regul, 2020, 77:100741.
[19] de Las Heras N, Martín GV, Ferder L, et al. Implications of oxidative stress and potential role of mitochondrial dysfunction in COVID-19: therapeutic effects of vitamin D[J]. Antioxidants(Basel), 2020, 9(9):897.
[20] Durante W. Targeting endoplasmic reticulum stress in hypoxia-induced cardiac injury[J]. Vascul Pharmacol, 2016, 83:1-3.
[21] Dubert M, Visseaux B, Isernia V, et al. Case report study of the first five COVID-19 patients treated with remdesivir in France[J]. Int J Infect Dis, 2020, 98:290-293.
[22] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus(2019-nCoV)[J]. Nat Rev Drug Discov, 2020, 19(3):149-150.
[23] Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques[J]. Nat Med, 2013, 19(10):1313-1317.
[24] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Res, 2020, 30(3):269-271.
[25] Zhang P, Zhu L, Cai J, et al. Association of inpatient use of Angiotensin-Converting enzyme inhibitors and angiotensin Ⅱ receptor blockers with mortality among patients with hypertension hospitalized with COVID-19[J]. Circ Res, 2020, 126(12):1671-1681.
[26] Ledford H. Coronavirus breakthrough:dexamethasone is first drug shown to save lives[J]. Nature, 2020, 582(7813):469.
[27] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet, 2020, 395(10223):473-475.
[28] Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19[J]. J Clin Invest, 2020, 130(4):1545-1548.
[29] Shen C, Wang ZQ, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma[J]. JAMA, 2020, 323(16):1582-1589.
[30] Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients[J]. Med Mal Infect, 2020, 50(5):397-400.
[31] Luo L, Jiang J, Wang C, et al. Analysis on herbal medicines utilized for treatment of COVID-19[J]. Acta Pharm Sin B, 2020, 10(7):1192-1204.
[32] Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2021, 85:153242.
[33] Alhazzani W, M?ller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)[J]. Crit Care Med, 2020, 48(6):e440-e469.
[34] Grant WB, Lahore H, Mcdonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths[J]. Nutrients, 2020, 12(4):988.

备注/Memo

备注/Memo:
基金项目:河北省自然科学基金精准医学联合基金重点项目(H2020206409); Chinese Cardiovascular Association-Access fund(2018-CCA-ACCESS-007)
通信作者:谷国强,E-mail:guguoqiang72@163.com
更新日期/Last Update: 2021-12-01